TABLE 4.
Disease severity assessed at different timepoints related to therapy continuation or discontinuation. Both patient‐assessed severity measurements—itch NRS score, sleep NRS score, AD‐NRS score, course of disease (improved, stable, worsened)—and physician‐assessed severity measure (EASI score) were performed in all patient population, in the subcohort of patients treated continuously, and in the subcohort of patients who discontinued treatment
| Patients continuing treatment (n. pts: 1580) | Patients discontinuing treatment (n. pts: 251) | Total population (n. pts: 1831) | |
|---|---|---|---|
| Timepoint 1 (lockdown‐ phase 1) | |||
| Mean EASI score (±SD) ç | 6.6 (7.8) # | 8.2 (7.5) # | 6.8 (7.7) |
| Mean itch NRS score (±SD) | 2.4 (2.1) | 3.7 (2.3) | 2.6 (2.2) |
| Mean sleep NRS score (±SD) | 1.6 (2.0) | 2.7 (2.4) | 1.7 (2.1) |
| AD‐NRS score (±SD) | 2.3 (2.0) | 3.5 (2.2) | 2.5 (2.1) |
| Self‐reported AD status § | |||
| Improved n. pts (%) | 454 (28.8%) | 39 (15.5%) | 493 (27.0%) |
| Stable n. pts (%) | 961 (60.9%) | 122 (48.6%) | 1083 (59.2%) |
| Worsened n. pts (%) | 162 (10.3%) | 90 (35.9%) | 252 (13.8%) |
| Timepoint 2 (phase 2) | |||
| Mean itch NRS score (±SD) | 2.4 (2.1) | 3.7 (2.3) | 2.6 (2.2) |
| Mean sleep NRS score (±SD) | 1.5 (1.8) | 2.8 (2.8) | 1.6 (2.0) |
| AD‐NRS score (±SD) | 2.1 (1.9) | 3.7 (2.6) | 2.3 (2.1) |
| Self‐reported AD status § | |||
| Improved n. pts (%) | 417 (27.2%) | 53 (22.1%) | 470 (26.5%) |
| Stable n. pts (%) | 980 (63.8%) | 102 (42.5%) | 1082 (61.0%) |
| Worsened n. pts (%) | 138 (9.0%) | 85 (35.4%) | 223 (12.6%) |
| Timepoint 3 (phase 3) | |||
| Mean EASI score (±SD) ç | 2.8 (3.4) | 7.3 (7.7) | 3.4 (4.4) |
| Mean itch NRS score (±SD) | 3.3 (2.6) | 3.3 (2.6) | 2.2 (2.1) |
| Mean sleep NRS score (±SD) | 1.2 (1.7) | 2.2 (2.4) | 1.3 (1.9) |
| AD‐NRS score (±SD) | 1.9 (1.9) | 3.0 (2.4) | 2.1 (2.0) |
| Self‐reported AD status § | |||
| Improved n. pts (%) | 442 (30.2%) | 69 (30.7%) | 511 (30.3%) |
| Stable n. pts (%) | 921 (62.9%) | 113 (50.2%) | 1034 (61.2%) |
| Worsened n. pts (%) | 101 (6.9%) | 43 (19.1%) | 144 (8.5%) |
| Change in EASI score from timepoint 1 to timepoint 3 | −2.8 (7.1) | −0.2 (7.7) | −2.5 (7.2)* |
| Change in itch NRS from timepoint 1 to timepoint 3 | −0.3 (2.0) | −0.2 (2.7) | −0.3 (2.1)* |
| Change in sleep NRS from timepoint 1 to timepoint 3 | −0.3 (1.9) | −0.3 (2.8) | −0.3 (2.0)* |
| Change in AD‐NRS from timepoint 1 to timepoint 3 | −0.4 (1.8) | −0.3 (2.4) | −0.4 (1.9)* |
Abbreviations: AD, atopic dermatitis; EASI: Eczema Area and Severity Index; NRS: Numeric Rating Scale; pts: patients; SD: standard deviation.
P < 0.001, Wilcoxon rank‐sum test was used to compare the 2 patient subcohorts at timepoint 1.
P < 0.001, chi‐squared test was used for statistical analysis.
Mean EASI score was calculated on 1831 and 746 patients at timepoint 1 and 3, respectively.
P < 0.0001, paired s test was used to compare T1 vs T3 in the total population.